Katherine A. McGlynn

McGlynn received a M.P.H. in population studies from Tulane University School of Public Health and Tropical Medicine. She completed a Ph.D. in epidemiology from the Perelman School of Medicine at the University of Pennsylvania.^[1] Her 1984 dissertation was titled Isoniazid and the hepatitis b carrier state in Southeast Asians in Philadelphia.^[2] W. Thomas London was her doctoral advisor and Edward D. Lustbader served as an advisor for statistical methods.^[2] She conducted postdoctoral research on liver cancer at the Fox Chase Cancer Center, where she subsequently served as a faculty member before coming to the National Cancer Institute (NCI) in 1998.^[1] She is a senior investigator in the NCI metabolic epidemiology branch in the division of cancer epidemiology and genetics (DCEG).^[1]

McGlynn uses different study designs to investigate environmental and genetic risk factors that may contribute to the increasing rates.^[1] She studies testicular dysgenesis syndrome (TDS) outcomes in complementary studies.^[1] Her TDS research includes maternal and son hormonal effects, endocrine-disrupting chemicals, and perinatal factors.^[1] McGlynn's TDS research focus is the relationship of steroid hormones and gonadotropins to the development of TDS outcomes.^[1] She also investigates the relationship of organochlorine compounds to several TDS outcomes.^[1] McGlynn researches liver cancer and whether medications such as non-steroidal anti-inflammatory drugs, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, diabetes medications and other drugs affect risk of hepatocellular carcinoma.^[1]